Evidence map›Paper›PMID 30650251›Full record

Trial reportProteomics. Clinical applications2019

Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse.

Fieke W Hoff, Chenyue W Hu, Amina A Qutub, Yihua Qiu, Marisa J Hornbaker, Carlos Bueso-Ramos, Hussein A Abbas, Sean M Post, Eveline S J M de Bont, Steven M Kornblau

Open access · hybridAbstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Proteomics. Clinical applications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Fieke W HoffDepartment of Pediatric Oncology/Hematology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, 9713, The Netherlands.ORCID 0000-0002-7128-1255
Chenyue W HuDepartment of Bioengineering, Rice University, Houston, TX, 77030, USA.
Amina A QutubDepartment of Biomedical Engineering, University of Texas San Antonio, San Antonio, TX, 78429, USA.
Yihua QiuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.
Marisa J HornbakerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.
Carlos Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Hussein A AbbasHematology and Oncology Fellowship Program, Cancer Medicine Division, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Sean M PostDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.
Eveline S J M de BontDepartment of Pediatric Oncology/Hematology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, 9713, The Netherlands.
Steven M KornblauDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.
The University of Texas MD Anderson Cancer Center · USUniversity Medical Center Groningen · NLRice University · USThe University of Texas at San Antonio · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
TRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8M
Personalized therapy for AML patients with a newly identified genetic alterationR01CA207204 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI POST, SEAN M · 2016 to 2020
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA207204NCI NIH HHS R01CA207204NCI NIH HHS T32 CA009666
6 · The paper itself

Abstract

purposeAcute promyelocytic leukemia (APL) is the most prognostically favorable subtype of Acute myeloid leukemia (AML). Defining the features that allow identification of APL patients likely to relapse after therapy remains challenging. EXPERIMENTAL

designProteomic profiling is performed on 20 newly diagnosed APL, 205 non-APL AML, and 10 normal CD34+ samples using Reverse Phase Protein Arrays probed with 230 antibodies.

resultsComparison between APL and non-APL AML samples identifies 8.3% of the proteins to be differentially expressed. Proteins higher expressed in APL are involved in the pro-apoptotic pathways or are linked to higher proliferation. The "MetaGalaxy" approach that considers proteins in relation to other assayed proteins stratifies the APL patients into two protein signatures. All of the relapse patients (n = 4/4) are in protein signature 2 (S2). Comparison of proteins between the signatures shows significant differences in relative expression for 38 proteins. Protein expression summary plots suggest less translational activity in combination with a less proliferative character for S2 compared to signature 1. CONCLUSIONS AND CLINICAL RELEVANCE: This study provides a potential proteomic-based classification of APL patients that may be useful for risk stratification and therapeutic guidance. Validation in a larger independent cohort is required.

Indexed as

Gene Expression ProfilingProtein Array AnalysisProteomicsAdolescentAdultAgedFemaleHumansLeukemia, Promyelocytic, AcuteMaleMiddle AgedNeoplasm ProteinsNeoplasm Proteinsacute myeloid leukemiaacute promyelocytic leukemialeukemiaproteomics reverse phase protein array

Identifiers

PMID30650251
PMCPMC6635093
OpenAlexW2910052807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.